Postinfectious Irritable Bowel Syndrome: Polemic and Open Issues
https://doi.org/10.22416/1382-4376-2021-31-6-41-46
Abstract
Aim. An analysis of polemic and open topics in epidemiology, pathogenesis, clinic, diagnosis and treatment of postinfectious irritable bowel syndrome (IBS).
Key points. The incidence of postinfectious IBS links to aetiological factors underlying the development of acute infectious gastroenteritis (bacteria, viruses or protozoans). The risk factors of postinfectious IBS have been identified: female gender, excessive anxiety, depression and somatisation, a severe sequence of acute infectious gastroenteritis, etc. The diagnosis of postinfectious IBS implies exclusion of organic diseases with similar clinical presentations. A specific postinfectious IBS treatment is currently lacking and adheres to non-postinfectious IBS strategies.
Conclusion. The postinfectious IBS problematic is poorly understood and requires further research.
About the Authors
A. A. Sheptulin
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Arkadiy A. Sheptulin — Dr. Sci. (Med.), Prof., Chair of Internal Disease Propaedeutics, Gastroenterology and Hepatology, Sklifosovsky Institute of Clinical Medicine,
119435, Moscow, Pogodinskaya str., 1, bld. 1
M. A. Vize-Khripunova
Ulyanovsk State University
Russian Federation
Russian Federation
Marina A. Vize-Khripunova — Cand. Sci. (Med.), Assoc. Prof., Head of the Chair of Hospital Therapy, Faculty of Medicine, Institute of Medicine, Ecology and Physical Education,
432017, Ulyanovsk, L. Tolstogo str., 42
References
1. Chaudhary N.A., Truelove S.C. The irritable colon syndrome. A study of the clinical features, predisposing causes and prognosis in 130 cases. Q J Med. 1962;31:307–22.
2. Riddle M.S., Connor P., Porter C.K. Montezuma’s revenge — the sequel: The one-hundred year anniversary of the first description of “post-infectious” irritable bowel syndrome. World J Gastroenterol. 2018;24(45):5076–80. DOI: 10.3748/wjg.v24.i45.5076
3. Lacy B.E., Mearin F., Chang L., Chey W.D., Lembo A.J., Simren M., Spiller R. Bowel disorders. Gastroenterology. 2016;150:1393–407. DOI: 10.1053/j.gastro.2016.02.031
4. Barbara G., Grover M., Bercik P., Corsetti M., Ghoshal U.C., Ohman L., Rajilic-Stojanovic M. Rome Foundation Working Team report on post-infection irritable bowel syndrome. Gastroenterology. 2019;156(1):46– 58. DOI: 10.1053/j.gastro.2018.07.011
5. Klem F., Wadhwa A., Prokop L.J., Sundt W.J., Farrugia G., Camilleri M., et al. Prevalence, risk factors and outcomes of irritable bowel syndrome after infectious enteritis: a systemic review and meta-analysis. Gastroenterology. 2017;152(5):1042–54. DOI: 10.1053/j.gastro.2016.12.039
6. Dayananda P., Wilcox M.H. Irritable bowel syndrome following Clostridium difficile infection. Curr Opin Gastroenterol. 2019;35(1):1–5. DOI: 10.1897/MOG.0000000000000490
7. Zanini B., Ricci C., Bandera F., Caselani F., Magni A., Laronga A.M., et al. Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak. Am J Gastroenterol. 2012;107(6):891–8. DOI: 10.1038/ajg.2012.102
8. Noviello D. Costantino A., Muscatello A., Bandera A., Consonni D., Vecchi M., Basilisko G. Functional gastrointestinal and somatoform symptoms four month after SARS-CoV-2 infection: A controlled cohort study. Neurogastroenterol Motil. 2021;e14187. DOI: 10.1111/nmo.14187
9. Kanazawa M., Palsson O.S., van Tiburg M.A.L., Gangarosa L.M., Fukudo S., Rhitehead W.E. Motility response to colonic distention is increased in postinfectious irritable bowel syndrome (PI-IBS). Neurogastroenterol Motil. 2014;26(5):6960704. DOI: 10.1111/nmo.12318
10. Jalanka J., Salonen A., Fuentes S. de Vos W.M. Microbial signatures in post-infectious irritable bowel syndrome — toward patient stratification for improved diagnostics and treatment. Gut Microbes. 2015;6(6):364–9. DOI: 10.1080/19490976.2015.1096486
11. Spiller R.C., Jenkins D., Thornley J.P., Hebden J., Wright T., Skinner M., et al. Increased rectal mucosal enteroendocrine cells, T-lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47(6):804–11. DOI: 1136/gut.47.6.804
12. Wang L.-H., Fang X.-C., Pan G.-Z. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut. 2004;53(8):1096–101. DOI: 10.1136/gut.2003.021154
13. Chen J.I. Chen J.I., Zhang Y., Deng Z. Imbalanced shift of cytokine expression between T helper 1 and T helper 2 (Th1/Th2) in intestinal mucosa of patients with postinfectious irritable bowel syndrome. BMC Gastroenterol. 2012;12:91.
14. Ivashkin V.T., Shelygin Yu. A., Baranskaya E.K., Belousova Ye. A., Beniashvili A.G., Vasilyev S.V., et al. Diagnosis and treatment of the irritable bowel syndrome: clinival guidelines of the Russian gastroenterological association and Russian association of coloproctology. Rus J Gastroenterol Hepatol Coloproctol. 2017;27(5):76–93 (In Russ.).
15. Shah A., Talley N.J., Jones M, Kendall BJ, Lolosri N, Walker M.M., et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis of case-control studies. Am J Gastroenterol. 2020;115(2):190–201. DOI: 10.14309/ajg.0000000000000504
16. Esposito I., de Leone A., Di Gregorio S., de Magistris L., Ferrieri A., Riegler G. Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics. World J Gastroenterol. 2007;13(45):6016–21. DOI: 10.3748/wjg.v13.45.6016
17. Samsonov A.A., Plotnikova E.Yu., Borsch M.V. Postinfectious irritable bowel syndrome I — a special form of functional intestinal pathology. Lechastshiy vrach. 2012;7:21–9 (In Russ.).
18. Cremon C., Stanghellinu V., Pallotti F., Fogacci E., Bellacosa L., Morselli-Lobato A.M., et al. Salmonella gastroenteritis during childhood is a risk factor for irritable bowel syndrome in adulthood. Gastroenterology. 2014;147(1):69–77. DOI: 10.1053/j.gastro.2014.03.013
19. Jin Y., Ren X., Li G., Li Y., Zhang L, Wang H., et al. Beneficial effects of Rifaximin in post-infectious irritable bowel syndrome mouse model beyond gut microbiota. J Gastroenterol Hepatol. 2018;33(2):443–52. DOI: 10.1111/jgh.13841
20. Сuoco L., Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol Dietol. 2006;52(1):89–95.
21. Peralta S., Cottone C., Doveri T., Almasio P.L., Craxi A. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin. World J Gastroenterol. 2009;15(21):2628–31. DOI: 10.3748/wjg.15.2628
22. Leventogiannis K., Gkolfakis P., Spithakis G., Tsatali A., Pistiki A., Sioulas A., et al. Effect of a preparation of four probiotics on symptoms of patients with irritable bowel syndrome: association with intestinal bacterial overgrowth. Probiotics Antimicrob Proteins. 2019;11(2):627– 34. DOI: 10.1007/s12602-018-9401-3
Review
For citations:
Sheptulin A.A., Vize-Khripunova M.A. Postinfectious Irritable Bowel Syndrome: Polemic and Open Issues. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(6):41-46. (In Russ.) https://doi.org/10.22416/1382-4376-2021-31-6-41-46
Views:
1367
Email this article 
